PremiumThe FlyRising High: Exclusive talk with biopharma company HMNC Brain Health Prothena partner Roche PADOVA study misses primary endpoint Roche announces PADOVA study misses statistical significance PremiumThe FlyRoche says five-year results confirm Polivy combo as ‘new standard of care’ Genentech announces FDA acceptance of Columvi combination sBLA Roche price target raised to CHF 230 from CHF 220 at JPMorgan PremiumThe FlyPoseida Therapeutics to be acquired by Roche for $9.00 per share plus CVR Roche announces FDA approval of label expansion into biliary tract cancer FDA grants accelerated approval to Jazz Pharmaceuticals’ Ziihera